YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells.


Journal

Developmental cell
ISSN: 1878-1551
Titre abrégé: Dev Cell
Pays: United States
ID NLM: 101120028

Informations de publication

Date de publication:
06 05 2019
Historique:
received: 10 03 2018
revised: 04 02 2019
accepted: 08 04 2019
entrez: 8 5 2019
pubmed: 8 5 2019
medline: 7 1 2020
Statut: ppublish

Résumé

Merlin/NF2 is a bona fide tumor suppressor whose mutations underlie inherited tumor syndrome neurofibromatosis type 2 (NF2), as well as various sporadic cancers including kidney cancer. Multiple Merlin/NF2 effector pathways including the Hippo-YAP/TAZ pathway have been identified. However, the molecular mechanisms underpinning the growth and survival of NF2-mutant tumors remain poorly understood. Using an inducible orthotopic kidney tumor model, we demonstrate that YAP/TAZ silencing is sufficient to induce regression of pre-established NF2-deficient tumors. Mechanistically, YAP/TAZ depletion diminishes glycolysis-dependent growth and increases mitochondrial respiration and reactive oxygen species (ROS) buildup, resulting in oxidative-stress-induced cell death when challenged by nutrient stress. Furthermore, we identify lysosome-mediated cAMP-PKA/EPAC-dependent activation of RAF-MEK-ERK signaling as a resistance mechanism to YAP/TAZ inhibition. Finally, unbiased analysis of TCGA primary kidney tumor transcriptomes confirms a positive correlation of a YAP/TAZ signature with glycolysis and inverse correlations with oxidative phosphorylation and lysosomal gene expression, supporting the clinical relevance of our findings.

Identifiants

pubmed: 31063758
pii: S1534-5807(19)30284-9
doi: 10.1016/j.devcel.2019.04.014
pmc: PMC6524954
mid: NIHMS1526767
pii:
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Neurofibromin 2 0
Trans-Activators 0
Transcription Factors 0
Transcriptional Coactivator with PDZ-Binding Motif Proteins 0
WWTR1 protein, human 0
YAP-Signaling Proteins 0
YAP1 protein, human 0
Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

425-443.e9

Subventions

Organisme : NCI NIH HHS
ID : P50 CA101942
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL134923
Pays : United States
Organisme : NIDCR NIH HHS
ID : R21 DE028670
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009686
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA187090
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA051008
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA193698
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

EMBO J. 2016 Mar 1;35(5):462-78
pubmed: 26668268
Mol Cell. 2017 Nov 2;68(3):591-604.e5
pubmed: 29100056
Nat Cell Biol. 2015 Jan;17(1):95-103
pubmed: 25438054
Hum Mol Genet. 2003 Jun 1;12(11):1211-21
pubmed: 12761036
Carcinogenesis. 2008 Nov;29(11):2139-46
pubmed: 18725387
FEBS J. 2006 Sep;273(18):4264-76
pubmed: 16930133
Cancer Discov. 2016 Nov;6(11):1258-1266
pubmed: 27604489
Circ Res. 2015 Jan 2;116(1):35-45
pubmed: 25249570
Mol Cell Biol. 2002 Jun;22(11):3717-28
pubmed: 11997508
EMBO J. 2018 Nov 15;37(22):
pubmed: 30348863
Oncotarget. 2014 Dec 30;5(24):12509-27
pubmed: 25587023
Cell Rep. 2016 Mar 15;14(10):2476-89
pubmed: 26947078
Dev Biol. 2012 Sep 1;369(1):115-23
pubmed: 22732571
J Clin Invest. 2018 Mar 1;128(3):1010-1025
pubmed: 29400692
Science. 1993 Nov 12;262(5136):1069-72
pubmed: 7694367
Eur Urol. 2016 Sep;70(3):516-21
pubmed: 26149668
Cell. 2012 Aug 17;150(4):780-91
pubmed: 22863277
Sci Signal. 2011 Oct 25;4(196):ra70
pubmed: 22028467
Genes Dev. 2013 Jun 1;27(11):1223-32
pubmed: 23752589
Dev Cell. 2001 Jul;1(1):63-72
pubmed: 11703924
Cell Metab. 2016 Nov 8;24(5):716-727
pubmed: 27746050
Cell. 2013 Sep 12;154(6):1342-55
pubmed: 24012335
N Engl J Med. 2016 Jan 14;374(2):135-45
pubmed: 26536169
J Cell Sci. 2013 May 1;126(Pt 9):1905-12
pubmed: 23720375
Cell Death Dis. 2016 Apr 21;7:e2198
pubmed: 27100892
Nat Commun. 2016 Oct 07;7:13131
pubmed: 27713405
Oncogene. 2016 Feb 4;35(5):537-48
pubmed: 25893302
Cancer Cell. 2014 Jul 14;26(1):48-60
pubmed: 25026211
Cell Metab. 2019 Jan 8;29(1):124-140.e10
pubmed: 30293773
Nat Cell Biol. 2016 Aug;18(8):886-896
pubmed: 27428308
Genes Dev. 2012 Sep 15;26(18):2027-37
pubmed: 22925885
Nature. 1998 Nov 12;396(6707):180-3
pubmed: 9823899
Eur Urol. 2016 Aug;70(2):348-57
pubmed: 26895810
Cancer Cell. 2015 Dec 14;28(6):743-757
pubmed: 26678338
J Biol Chem. 1999 Jul 16;274(29):20281-6
pubmed: 10400647
Cancer Res. 2006 Oct 1;66(19):9483-91
pubmed: 17018604
Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15038-43
pubmed: 17015830
Nat Cell Biol. 2015 Jun;17(6):793-803
pubmed: 25961504
Nat Commun. 2017 Jan 19;8:14073
pubmed: 28102225
Nat Cell Biol. 2012 Dec;14(12):1322-9
pubmed: 23143395
Oncogene. 2009 Feb 12;28(6):854-65
pubmed: 19029950
Oncotarget. 2018 Jan 10;9(12):10723-10733
pubmed: 29535838
Nat Cell Biol. 2017 Apr;19(4):362-374
pubmed: 28346439
Nature. 2017 Jun 22;546(7659):498-503
pubmed: 28607485
Cancer Res. 2016 Jun 15;76(12):3507-19
pubmed: 27216189
Mol Cell. 2018 Oct 18;72(2):328-340.e8
pubmed: 30293781
Dev Cell. 2016 Nov 21;39(4):452-465
pubmed: 27818180
Oncogene. 2012 Dec 6;31(49):5117-22
pubmed: 22286761
Cancer Res. 2004 Feb 1;64(3):985-93
pubmed: 14871829
Cell Rep. 2017 May 9;19(6):1083-1090
pubmed: 28494858
J Clin Invest. 2016 Sep 1;126(9):3313-35
pubmed: 27548520
Eur J Cancer. 2013 Jul;49(11):2608-18
pubmed: 23566416
Cell Rep. 2018 Apr 3;23(1):313-326.e5
pubmed: 29617669
Gastroenterology. 2018 Apr;154(5):1465-1479.e13
pubmed: 29305935
Cell Metab. 2014 Apr 1;19(4):630-41
pubmed: 24703695
J Biol Chem. 2010 Nov 26;285(48):37159-69
pubmed: 20858893
Cell. 2007 Sep 21;130(6):1120-33
pubmed: 17889654
Am J Physiol. 1994 Aug;267(2 Pt 1):C313-39
pubmed: 8074170
Eur Urol. 2018 Jan;73(1):71-78
pubmed: 28592388
Proc Natl Acad Sci U S A. 2010 Dec 7;107(49):21064-9
pubmed: 21078993
Am J Med Genet A. 2012 Jan;158A(1):24-41
pubmed: 22140088
J Biol Chem. 2017 Oct 13;292(41):17046-17056
pubmed: 28848049
J Neurosci. 2006 Mar 29;26(13):3390-5
pubmed: 16571745
Oncogene. 2002 Mar 28;21(14):2236-44
pubmed: 11948406
Nat Cell Biol. 2015 Apr;17(4):500-10
pubmed: 25751140
J Biol Chem. 1997 Jul 11;272(28):17269-75
pubmed: 9211863
Mol Cell Biol. 2002 Sep;22(17):6023-33
pubmed: 12167697
Cell. 2014 Jun 5;157(6):1324-38
pubmed: 24906150
Neoplasia. 2008 Nov;10(11):1204-12
pubmed: 18953429
Genes Dev. 2007 Nov 1;21(21):2747-61
pubmed: 17974916
J Exp Med. 2014 Oct 20;211(11):2249-63
pubmed: 25288394
J Biol Chem. 2003 Oct 10;278(41):39337-48
pubmed: 12869574
Cancer Res. 2007 Jan 15;67(2):520-7
pubmed: 17234759
Brain Pathol. 2009 Jan;19(1):27-38
pubmed: 18445079
EMBO J. 2013 May 29;32(11):1543-55
pubmed: 23644383
Nat Cell Biol. 2014 Apr;16(4):357-66
pubmed: 24658687
Genes Dev. 2008 Jul 15;22(14):1962-71
pubmed: 18579750
Trends Cell Biol. 2016 Apr;26(4):289-299
pubmed: 26750334
Cancer Cell. 2011 Apr 12;19(4):527-40
pubmed: 21481793
Methods Enzymol. 2015;561:171-96
pubmed: 26358905
Nat Cell Biol. 2015 Apr;17(4):490-9
pubmed: 25751139
Mol Cell Biol. 2003 Oct;23(20):7315-28
pubmed: 14517300
Dev Cell. 2010 Feb 16;18(2):288-99
pubmed: 20159598
J Reprod Fertil. 1990 Jan;88(1):231-9
pubmed: 2313640
J Cell Biol. 2004 Feb 16;164(4):527-34
pubmed: 14769862
Nat Genet. 2015 Jan;47(1):13-21
pubmed: 25401301
Nature. 2015 Aug 20;524(7565):361-5
pubmed: 26168401
Genes Dev. 2001 Jun 1;15(11):1406-18
pubmed: 11390360
Cytometry A. 2014 Aug;85(8):729-37
pubmed: 24953340
Physiol Rev. 1990 Apr;70(2):391-425
pubmed: 2157230
Cell. 2005 Aug 12;122(3):421-34
pubmed: 16096061
Cell. 2010 Feb 19;140(4):477-90
pubmed: 20178741
Cancer Res. 2017 Apr 1;77(7):1637-1648
pubmed: 28202507
PLoS One. 2016 May 02;11(5):e0154684
pubmed: 27136098
Nat Rev Mol Cell Biol. 2010 Jan;11(1):50-61
pubmed: 19997129
Nat Genet. 2015 Mar;47(3):250-6
pubmed: 25665005
Nat Cell Biol. 2009 Dec;11(12):1444-50
pubmed: 19935651
Oncotarget. 2015 May 20;6(14):11768-78
pubmed: 26059435
Mol Cell Biol. 2009 Mar;29(6):1472-86
pubmed: 19103750
Science. 2011 Jun 17;332(6036):1429-33
pubmed: 21617040
Cell. 2002 Aug 23;110(4):467-78
pubmed: 12202036
Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18200-5
pubmed: 15598747
Genes Dev. 2010 Aug 15;24(16):1718-30
pubmed: 20675406
Autophagy. 2016 Oct 2;12(10):1954-1955
pubmed: 27485905
Genetics. 2016 Aug;203(4):1777-88
pubmed: 27317679
J Cell Biol. 2003 Jul 21;162(2):281-91
pubmed: 12876277
Mol Biol Cell. 2007 Apr;18(4):1437-46
pubmed: 17301289
EMBO J. 2017 Nov 15;36(22):3325-3335
pubmed: 28963395
Nature. 1993 May 6;363(6424):85-8
pubmed: 8479541
EMBO J. 2015 May 12;34(10):1349-70
pubmed: 25796446
Nature. 2010 Jan 21;463(7279):360-3
pubmed: 20054297
Nat Commun. 2017 May 05;8:15280
pubmed: 28474680
Nat Commun. 2013;4:2799
pubmed: 24240988
Dev Cell. 2010 Jul 20;19(1):27-38
pubmed: 20643348
Mol Cell. 2016 Dec 1;64(5):993-1008
pubmed: 27912098
J Neurooncol. 2015 Apr;122(2):313-20
pubmed: 25567352
Mol Cell. 2004 Dec 3;16(5):819-30
pubmed: 15574336

Auteurs

Shannon M White (SM)

Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA.

Maria Laura Avantaggiati (ML)

Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA.

Ivan Nemazanyy (I)

Institut National de la Santé et de la Recherche Médicale (INSERM), U1151, Institut Necker Enfants Malades, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

Cristina Di Poto (C)

Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA.

Yang Yang (Y)

Department of Systems Pharmacology and Translational Therapeutics, Perelmen School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Mario Pende (M)

Institut National de la Santé et de la Recherche Médicale (INSERM), U1151, Institut Necker Enfants Malades, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

Geoffrey T Gibney (GT)

Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA.

Habtom W Ressom (HW)

Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA.

Jeffery Field (J)

Department of Systems Pharmacology and Translational Therapeutics, Perelmen School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Michael B Atkins (MB)

Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA.

Chunling Yi (C)

Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington DC, USA. Electronic address: cy232@georgetown.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH